Description: Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.
Home Page: valneva.com
6 rue Alain Bombard
Saint-Herblain,
44800
France
Phone:
33 2 28 07 37 10
Officers
Name | Title |
---|---|
Mr. Thomas Lingelbach | President, CEO & Director |
Mr. Peter Buhler | Chief Financial Officer |
Mr. Franck Grimaud MBA | Chief Business Officer |
Dr. Juan-Carlos Jaramillo M.D. | Chief Medical Officer |
Ms. Dipal Patel | Chief Commercial Officer |
Mr. Vincent Dequenne | Chief Operating Officer |
Dr. Hanneke Schuitemaker Ph.D. | Chief Scientific Officer |
Mr. Joshua Drumm Ph.D. | Vice President of Investor Relations |
Ms. Laetitia Bachelot-Fontaine | VP of Global Communications & European Investor Relations |
Ms. Petra Pesendorfer | Chief People Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 666.6667 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.4071 |
Price-to-Sales TTM: | 2.0928 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 676 |